- Home
- CLNN vs OTLK Comparison
CLNN vs OTLK Comparison
Compare CLNN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- OTLK
- Stock Information
- Founded
- CLNN 2012
- OTLK 2010
- Country
- CLNN United States
- OTLK United States
- Employees
- CLNN N/A
- OTLK N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLNN Health Care
- OTLK Health Care
- Exchange
- CLNN Nasdaq
- OTLK Nasdaq
- Market Cap
- CLNN 57.9M
- OTLK 48.3M
- IPO Year
- CLNN N/A
- OTLK 2016
- Fundamental
- Price
- CLNN $6.17
- OTLK $1.02
- Analyst Decision
- CLNN Strong Buy
- OTLK Buy
- Analyst Count
- CLNN 6
- OTLK 5
- Target Price
- CLNN $32.67
- OTLK $8.50
- AVG Volume (30 Days)
- CLNN 117.0K
- OTLK 8.0M
- Earning Date
- CLNN 11-12-2025
- OTLK 08-14-2025
- Dividend Yield
- CLNN N/A
- OTLK N/A
- EPS Growth
- CLNN N/A
- OTLK N/A
- EPS
- CLNN N/A
- OTLK N/A
- Revenue
- CLNN $286,000.00
- OTLK $1,505,322.00
- Revenue This Year
- CLNN N/A
- OTLK N/A
- Revenue Next Year
- CLNN $2,178.18
- OTLK $484.88
- P/E Ratio
- CLNN N/A
- OTLK N/A
- Revenue Growth
- CLNN N/A
- OTLK N/A
- 52 Week Low
- CLNN $2.28
- OTLK $0.79
- 52 Week High
- CLNN $7.10
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- CLNN 59.58
- OTLK 36.21
- Support Level
- CLNN $5.77
- OTLK $1.02
- Resistance Level
- CLNN $6.54
- OTLK $1.19
- Average True Range (ATR)
- CLNN 0.57
- OTLK 0.14
- MACD
- CLNN -0.04
- OTLK -0.01
- Stochastic Oscillator
- CLNN 53.03
- OTLK 53.49
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.